We can reverse the course of disease.
Generian is working to restore cellular function, amplifying natural signaling networks to reverse the course of disease.
Aging is the predominant risk factor for most diseases.
Over time, cells no longer function as they should – impacting signaling networks that drive cellular stress, leading to chronic disorders. Generian is using insights about the natural process of cellular aging to develop therapies that restore cellular function, amplifying natural signaling networks to reverse the course of disease.
Generian’s discovery platform harnesses E3 ligase biology to enhance the activation of beneficial cellular pathways. Our medicines increase specific target protein activity and improve cellular function and healthspan by restoring signaling through the body’s natural biological networks.
Leveraging decades of research from some of the foremost experts in age-related diseases and E3 ligase biology, Generian has identified network regulators (TFEB and AMPK) which are validated therapeutic targets essential to cellular function that diminish with age, disease or genetic mutations. Generian’s programs provide an opportunity for clinical proof of mechanism and validation in rare conditions, with expansion into common disorders.
TFEB (or Transcription Factor EB)
plays an essential role in cellular quality control by regulating autophagy and lysosomal biogenesis.
AMPK (or AMP-activated protein kinase)
helps to maintain cellular fitness, playing an essential role in nutrient sensing and appropriate cell metabolism.